companydata.dkcompanydata.dk

KeasClinical Studies ApS: Financial statements 2024

CVR: 40794492

Source: annual report 2024, Danish Business Authority

01/01/2024 – 31/12/2024

KeasClinical Studies ApS (CVR 40794492) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -658 and a net result of DKK -607 compared with DKK -7,486 the year before. Equity in the 2024 report amounted to DKK 92,670. The solvency ratio was 76.2%.

Gross Profit
DKK -658
Profit/Loss
DKK -607
Equity
DKK 92,670
Total Assets
DKK 121,540

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024--658-60793 t.-
2023--8 t.-7 t.93 t.-
2022--23 t.-10 t.303 t.-
2021-151 t.113 t.663 t.0

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2024

Mette Albinus Grønbæk registered as owner of KeasClinical Studies ApSSep 24, 2024

As of September 24, 2024, Mette Albinus Grønbæk is registered as an owner of KeasClinical Studies ApS with an ownership share of 5%.

Blitz Holding ApS registered as owner of KeasClinical Studies ApSSep 24, 2024

As of September 24, 2024, Blitz Holding ApS is registered as an owner of KeasClinical Studies ApS with an ownership share of 90%.

Lone Bliksted Gitz-Johansen joins KeasClinical Studies ApS as directorAug 31, 2024

As of August 31, 2024, Lone Bliksted Gitz-Johansen is registered as director of KeasClinical Studies ApS.

Janus Bliksted Gitz-Johansen steps down as director of KeasClinical Studies ApSAug 31, 2024

As of August 31, 2024, Janus Bliksted Gitz-Johansen has stepped down as director of KeasClinical Studies ApS.

Blitz Technology ApS changes name to KeasClinical Studies ApSAug 31, 2024

On August 31, 2024, the company changed its name from Blitz Technology ApS to KeasClinical Studies ApS.

KeasClinical Studies ApS: The 2023 annual report is outJun 30, 2024

KeasClinical Studies ApS has published its annual report for 2023. Gross profit came to DKK -7,500, and the net result was DKK -7,486.

About KeasClinical Studies ApS

KeasClinical Studies ApS is a Danish company of the type Anpartsselskab based in Aarhus C, founded in 2019. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The company was previously named Blitz Technology ApS. The management consists of Lone Bliksted Gitz-Johansen. The company is owned by Mette Albinus Grønbæk and Blitz Holding ApS. The company has 1 employee (2020). In 2025, the company reported a gross profit of DKK -23,492 and a net result of DKK -14,372 compared with DKK -607 the year before. Equity in the 2025 report amounted to DKK 78,298.

Source: annual report 2025, Danish Business Authority

Other financial years